The Institute for Clinical and Economic Review (ICER) and researchers at NORC at the University of Chicago released a white paper that looks at the future of affordability and sustainability of drug development for rare disease through the lens of 4 policy proposals.
A white paper released this month examines 4 policy proposals that aim to address innovation and affordability in the realm of orphan drug development for rare diseases, including pricing and coverage.
The report was released by the Institute for Clinical and Economic Review (ICER) in collaboration with researchers at NORC at the University of Chicago.
“The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability” does not advocate for any specific solution, ICER said. The white paper is the result of a meeting in December 2021, which included representatives from rare disease patient groups and ICER’s Policy Leadership Forum, which is made up of 30 payer and life science companies.
In 1983, Congress passed the landmark Orphan Drug Act (ODA), which created financial incentives to encourage companies to develop new drugs for rare diseases, including tax credits to offset some research and development costs; eligible products receive an extended 7-year market exclusivity.
However, in recent years, these products and their pricing have come under intense scrutiny, as several reports have noted that drugs with the orphan drug designation generate much of their use—and their resulting revenue—through expanded indications for diseases that are not rare.
In turn, this has led to concern about future sustainability, including for the development of ultra-rare diseases, which lack treatment.
Treatments for ultra-rare conditions remain elusive, ICER said. The purpose of the paper was to present policymakers with the pros and cons of various reforms to “improve evidence generation, boost the chances for treatments of ultra-rare diseases, and reduce the prices for treatments whose clinical benefits do merit traditional 'orphan drug' level pricing.”
More than 50% of FDA drug approvals now have the orphan designation, and a number of other policy developments and scientific advances since 1983 that should, in theory, facilitate development of these drugs exist, the paper noted, although that idea is also contested.
“To secure a future in which innovation and affordability are both ensured, policymakers are going to have to consider potential reforms,” said Steven Pearson, MD, MSc, ICER’s president.
The potential reforms include:
Each proposal has its own set of trade-offs, the authors note. For instance, the rare disease community—patients and advocates—are not in favor of a narrower bar for what is considered an “ultra rare” disease. European health care systems, for instance, use the threshold of 10,000 patients in determining whether a disease is ultra rare. In the United States, advocates fear that incentives to support innovation would fall over time and might not take into account quality-of-life issues.
Those who prefer the status quo are not likely to favor any of the proposed reforms, the paper noted, but broad access to continued innovation is at stake, the authors said.
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More